Nasdaq

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) ...
Seeking Alpha

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway ...
Seeking Alpha

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation The granted patent covers claims ...
Nasdaq

GRI Bio, Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that it has regained compliance with Nasdaq ...
The Manila Times

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of ...